| Q36088887 | A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus-Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study |
| Q53324683 | A new rescue regimen with plasma exchange and rituximab in high-risk membranous glomerulonephritis. |
| Q60045363 | Analysis of predictive factors for immunosuppressive response in anti-phospholipase A2 receptor antibody positive membranous nephropathy |
| Q34701007 | Autoantibodies against phospholipase A2 receptor in Korean patients with membranous nephropathy |
| Q49208897 | BAFF and APRIL expression as an autoimmune signature of membranous nephropathy |
| Q42639047 | Balancing cancer risk and efficacy of using cyclophosphamide to treat idiopathic membranous nephropathy |
| Q47579012 | Benefits of cyclosporine absorption profiling in nephrotic syndrome: preprandial once-daily administration of cyclosporine microemulsion improves slow absorption and can standardize the absorption profile |
| Q87393375 | Chapter 7: Idiopathic membranous nephropathy |
| Q36265388 | Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series. |
| Q41229115 | Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis. |
| Q90067724 | Comparative efficacy of 13 immunosuppressive agents for idiopathic membranous nephropathy in adults with nephrotic syndrome: a systematic review and network meta-analysis |
| Q36314982 | Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy |
| Q34248343 | Controversies in the treatment of idiopathic membranous nephropathy |
| Q82615406 | Cyclosporine versus azathioprine therapy in high-risk idiopathic membranous nephropathy patients: A 3-year prospective study |
| Q36596888 | Depletion of B lymphocytes in idiopathic membranous glomerulopathy: results from patients with extended follow-up |
| Q46563654 | Does cyclosporine achieve a real advantage for treatment of idiopathic nephrotic syndrome in children? A long-term efficacy and safety study |
| Q33805412 | Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis |
| Q35025425 | Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset |
| Q37516426 | Effect of steroid and cyclosporine in membranous nephropathy that is resistant to steroid and/or cytotoxic treatment |
| Q94526062 | Effects of CYP3A5 Polymorphisms on Efficacy and Safety of Tacrolimus Therapy in Patients with Idiopathic Membranous Nephropathy |
| Q57702077 | Efficacy and Safety of Rituximab Second-Line Therapy for Membranous Nephropathy: A Prospective, Matched-Cohort Study |
| Q91905580 | Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: a meta-analysis |
| Q57821643 | Efficacy of Traditional Chinese Medicine Regimen Jian Pi Qu Shi Formula for Refractory Patients with Idiopathic Membranous Nephropathy: A Retrospective Case-Series Study |
| Q44420378 | Efficacy of mizoribine followed by low-dose prednisone in patients with idiopathic membranous nephropathy and nephrotic-range proteinuria |
| Q35602657 | Emerging drugs for renal failure |
| Q84978295 | Evidence-based practice guideline for the treatment of CKD |
| Q36485751 | Experience of anti-viral therapy in hepatitis B-associated membranous nephropathy, including Lamivudine-resistant strains |
| Q92475956 | Identification of biomarkers and drug repurposing candidates based on an immune-, inflammation- and membranous glomerulonephritis-associated triplets network for membranous glomerulonephritis |
| Q38972849 | Identifying the ideal metric of proteinuria as a predictor of renal outcome in idiopathic glomerulonephritis |
| Q38508902 | Idiopathic membranous nephropathy in children |
| Q37543422 | Idiopathic membranous nephropathy: management strategies |
| Q36810470 | Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials |
| Q36662933 | Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial |
| Q34484801 | Immunosuppressive Medications |
| Q92564102 | Immunosuppressive regimens based on Cyclophospamide or Calcineurin inhibitors: Comparison of their effect in the long term outcome of Primary Membranous Nephropathy |
| Q24193098 | Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome |
| Q24246172 | Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome |
| Q37822152 | Individualizing early use of sirolimus in renal transplantation |
| Q79799147 | Is low-dose ciclosporin an effective treatment for membranous nephropathy with nephrotic syndrome? |
| Q37013035 | Latest treatment strategies for membranous nephropathy. |
| Q33894748 | Long-term Low-density Lipoprotein Apheresis in a Patient with Refractory Idiopathic Membranous Glomerulonephritis |
| Q51246368 | Long-term outcomes of initial therapy for idiopathic membranous nephropathy. |
| Q40105860 | Long-term outcomes of persistent disease and relapse in primary membranous nephropathy |
| Q50204894 | Low-dose cyclosporine in treatment of membranous nephropathy with nephrotic syndrome: effectiveness and renal safety. |
| Q43430971 | Lupus-like membranous nephropathy: Is it lupus or not? |
| Q34455214 | M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy |
| Q92833510 | MENTOR heralds a new era of therapy for membranous nephropathy |
| Q26740477 | Management of Membranous Nephropathy in Western Countries |
| Q37779802 | Management of idiopathic membranous nephropathy |
| Q93062730 | Membranous Nephropathy (MN) Recurrence After Renal Transplantation |
| Q36167127 | Membranous Nephropathy: Quantifying Remission Duration on Outcome |
| Q37291040 | Membranous glomerulonephritis: treatment response and outcome in children |
| Q33920367 | Membranous nephropathy in children: clinical presentation and therapeutic approach |
| Q36922222 | Membranous nephropathy in the older adult: epidemiology, diagnosis and management |
| Q39337229 | Membranous nephropathy-one morphologic pattern with different diseases |
| Q37475696 | Membranous nephropathy: Pilot study of a novel regimen combining cyclosporine and Rituximab |
| Q36970147 | Membranous nephropathy: Treatment outline and risk stratification |
| Q38733002 | Membranous nephropathy: thinking through the therapeutic options |
| Q80212414 | Membranous nephropathy: when and how to treat |
| Q44623298 | Membran�se Glomerulonephritis |
| Q47168526 | Mizoribine therapy combined with steroids and mizoribine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome |
| Q51520423 | More stable and reliable pharmacokinetics with preprandial administration of cyclosporine compared with postprandial administration in patients with refractory nephrotic syndrome. |
| Q33187621 | Mycophenolate mofetil and cyclosporine therapy in membranous nephropathy |
| Q43232395 | Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome |
| Q34481499 | Novel approaches in the treatment of lupus nephritis |
| Q34374122 | Patient age and the prognosis of idiopathic membranous nephropathy |
| Q48378237 | Peptide GAM immunoadsorption therapy in primary membranous nephropathy (PRISM): Phase II trial investigating the safety and feasibility of peptide GAM immunoadsorption in anti-PLA2 R positive primary membranous nephropathy. |
| Q36106413 | Pharmacological treatment of primary membranous nephropathy in 2016. |
| Q57701454 | Pharmacotherapy options for membranous nephropathy |
| Q82845255 | Preprandial microemulsion cyclosporine administration is effective for patients with refractory nephrotic syndrome |
| Q42636720 | Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome |
| Q37146440 | Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy |
| Q47193282 | Recurrence of primary glomerulonephritis: Review of the current evidence |
| Q57945954 | References |
| Q52573157 | Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study. |
| Q37251705 | Remission of proteinuria in primary glomerulonephritis: we know the goal but do we know the price? |
| Q83006795 | Renal pathology in idiopathic membranous nephropathy: a new perspective |
| Q46404634 | Response to 'Tacrolimus in membranous nephropathy'. |
| Q40977727 | Response to immunosuppressive therapy in PLA2R- associated and non-PLA2R- associated idiopathic membranous nephropathy: a retrospective, multicenter cohort study |
| Q39648546 | Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. |
| Q36109197 | Rituximab in idiopathic membranous nephropathy |
| Q37412829 | Rituximab therapy for membranous nephropathy: a systematic review |
| Q34362660 | Rituximab therapy in idiopathic membranous nephropathy: a 2-year study |
| Q94673545 | Serum Albumin at Partial Remission Predicts Outcomes in Membranous Nephropathy |
| Q34324240 | Significance of combined cyclosporine-prednisolone therapy and cyclosporine blood concentration monitoring for idiopathic membranous nephropathy with steroid-resistant nephrotic syndrome: a randomized controlled multicenter trial |
| Q36674174 | Sirolimus-associated proteinuria and renal dysfunction |
| Q37103758 | Slowing chronic kidney disease progression: results of prospective clinical trials in adults |
| Q33806897 | Smoking is a risk factor for the progression of idiopathic membranous nephropathy |
| Q33748541 | Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy |
| Q36872799 | Stepwise treatment using corticosteroids alone and in combination with cyclosporine in korean patients with idiopathic membranous nephropathy |
| Q85723222 | Study of mizoribine therapy in elderly patients with membranous nephropathy: comparison with patients not receiving mizoribine |
| Q37211086 | Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients |
| Q79529994 | TNFA2 and d2 alleles of the tumor necrosis factor alpha gene polymorphism are associated with onset/occurrence of idiopathic membranous nephropathy |
| Q36861628 | Tacrolimus in the treatment of idiopathic nephrotic syndrome. |
| Q80008151 | Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial |
| Q50019614 | The Effect of Mycophenolate Mofetil versus Cyclosporine as Combination Therapy with Low Dose Corticosteroids in High-risk Patients with Idiopathic Membranous Nephropathy: a Multicenter Randomized Trial. |
| Q38034908 | The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines--application to the individual patient |
| Q90136673 | The Many Faces of Calcineurin Inhibitor Toxicity-What the FK? |
| Q35310613 | The need for improved uptake of the KDIGO glomerulonephritis guidelines into clinical practice in Canada: a survey of nephrologists |
| Q47857626 | The population-level costs of immunosuppression medications for the treatment of glomerulonephritis are increasing over time due to changing patterns of practice |
| Q80031217 | Treatment aspects of primary nephrotic syndrome in adults |
| Q36280345 | Treatment of idiopathic membranous nephropathy |
| Q87035617 | Treatment of idiopathic membranous nephropathy |
| Q39410091 | Treatment of membranous nephropathy: time for a paradigm shift |
| Q51742747 | Treatment of nephrotic idiopathic membranous nephropathy with monthly i.v. pulse cyclophosphamide and oral steroids: a single centre's retrospective study. |
| Q24632899 | Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel |
| Q47850601 | Treatment of primary membranous nephropathy: where are we now? |
| Q42654718 | Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial |
| Q37511019 | Treatment with rituximab in idiopathic membranous nephropathy |
| Q45348164 | Two-Year Follow-up Study of Membranous Nephropathy Treated With Tacrolimus and Corticosteroids Versus Cyclical Corticosteroids and Cyclophosphamide |
| Q45351919 | What is the role of rituximab in idiopathic membranous nephropathy? |
| Q79181938 | [Treatment of glomerulonephritis] |